Major CalciMedica (CALC) holder receives new Series A and B warrants
Rhea-AI Filing Summary
CalciMedica, Inc. (CALC) reported that major stockholder ALAFI CAPITAL CO LLC acquired two new warrant positions on August 19, 2026. The holder received 3,529,192 Series A Warrants exercisable into the same number of common shares at $0.8033 per share and 3,529,192 Series B Warrants at an exercise price of $1.00 per share. The Series A Warrants expire on the earlier of 18 months after the closing date of a related private placement or 30 days following CalciMedica’s public announcement of FDA clearance of its Investigational New Drug Application for CM5480, while the Series B Warrants expire on June 23, 2031. After these transactions, ALAFI CAPITAL CO LLC directly holds 5,112,345 shares of CalciMedica common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
ALAFI CAPITAL CO LLC
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series A Warrants F1, F2 | 3,529,192 | $0.00 | $0.00 |
| Grant/Award | Series B Warrants F3 | 3,529,192 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Series A Warrants — 3,529,192 shares (Direct);
Series B Warrants — 3,529,192 shares (Direct);
Common Stock — 5,112,345 shares (Direct)
Footnotes (3)
- F1. The issue date of the Series A Warrants is August 19, 2026.
- F2. The expiration of these Series A Warrants is the earlier of (i) 18 months after the closing date of the Private Placement and (ii) 30 days following the Issuer's public announcement of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480.
- F3. The issue date of the Series B Warrants is August 19, 2026.
Key Figures
Series A Warrants acquired: 3,529,192 warrants
Series A Warrant exercise price: $0.8033 per share
Series B Warrants acquired: 3,529,192 warrants
+5 more
8 metrics
Series A Warrants acquired
3,529,192 warrants
Grant to ALAFI CAPITAL CO LLC on August 19, 2026
Series A Warrant exercise price
$0.8033 per share
Conversion or exercise price for underlying common stock
Series B Warrants acquired
3,529,192 warrants
Grant to ALAFI CAPITAL CO LLC on August 19, 2026
Series B Warrant exercise price
$1.0000 per share
Conversion or exercise price for underlying common stock
Series B Warrant expiration date
June 23, 2031
Expiration of Series B Warrants
Common stock held after transaction
5,112,345 shares
Direct holdings of ALAFI CAPITAL CO LLC following reported transactions
Series A Warrant issue date
August 19, 2026
Issue date disclosed in footnote F1
Series B Warrant issue date
August 19, 2026
Issue date disclosed in footnote F3
Key Terms
Series A Warrants, Series B Warrants, Private Placement, Investigational New Drug Application, +1 more
5 terms
Series A Warrants financial
"The issue date of the Series A Warrants is August 19, 2026."
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
Series B Warrants financial
"The issue date of the Series B Warrants is August 19, 2026."
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
Private Placement financial
"18 months after the closing date of the Private Placement and (ii) 30 days"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Investigational New Drug Application medical
"clearance of its Investigational New Drug Application by the U.S. Food"
An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.
U.S. Food and Drug Administration medical
"Drug Application by the U.S. Food and Drug Administration for CM5480."
The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.
FAQ
What did ALAFI CAPITAL CO LLC acquire in this Form 4 for CALC?
ALAFI CAPITAL CO LLC acquired 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, each exercisable for the same number of CalciMedica common shares, in grant-type transactions dated August 19, 2026.
What are the exercise prices of the new CalciMedica (CALC) warrants?
The Series A Warrants have an exercise price of $0.8033 per share, and the Series B Warrants have an exercise price of $1.00 per share, each for CalciMedica common stock.
When do the CalciMedica (CALC) Series A and Series B Warrants expire?
The Series A Warrants expire on the earlier of 18 months after the private placement closing or 30 days after public announcement of FDA clearance of the IND for CM5480. The Series B Warrants expire on June 23, 2031.
Are the CalciMedica (CALC) transactions reported under a Rule 10b5-1 plan?
No. The filing’s Rule 10b5-1 checkbox is not affirmed, indicating these warrant acquisitions were not reported as made pursuant to a Rule 10b5-1 trading plan.
What underlying security do the new CalciMedica (CALC) warrants relate to?
Both the Series A and Series B Warrants are exercisable for CalciMedica Common Stock, with each warrant series covering 3,529,192 underlying shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
